At the UBS presentation, CEO Macaluso stated (a) AMPE is currently in “very, very late stage negotiations” with a big pharma “partner” concerning Zertane. (b) Ampion has 28 already issued patents and an additional 30 patents pending; the first of two parts of the run-in study is already completed, and data will be available in the third quarter of this year (c) Optina is in late stage clinical trials, and data will be available in the fourth quarter (d) Luoxis is already funded.
Dr. Clift stated that Ampion has demonstrated prolonged relief of the osteoarthritis of the knee condition, and the drug is now in development. Dr. Clift also stated that efficacy of Optina for DME has been demonstrated in the Canadian study, specifically that it will stop vessels from leaking, decreasing edema in the back of the eye.
The UBS presentation is extremely informative; I recommend listening to it several times over.
I also very highly recommend consulting the official 8-K filing of June 3rd. It will give you details on the progress to date. In addition, there is considerable material available on the Ampio website.